<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01514357</url>
  </required_header>
  <id_info>
    <org_study_id>11-001372</org_study_id>
    <secondary_id>UL1RR024150</secondary_id>
    <nct_id>NCT01514357</nct_id>
  </id_info>
  <brief_title>Nesiritide in Resistant Hypertension</brief_title>
  <official_title>Novel Peptides in Resistant Human Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John C Burnett</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: If the use of B-type natriuretic peptide (BNP) is proven to be effective in&#xD;
      controlling high blood pressure, it may lead to a reduction of standard therapy and improved&#xD;
      cardiovascular and kidney protection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertension remains a global burden in cardiovascular disease leading to stroke, myocardial&#xD;
      infarction, and heart failure. Its myocardial complications result from increased mechanical&#xD;
      load on the heart. Under physiological conditions of increased myocardial load and resulting&#xD;
      myocardial stretch, atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP)&#xD;
      synthesis and secretion occur contributing to maintenance of optimal cardiorenal and blood&#xD;
      pressure homeostasis. However, studies indicate that in subjects with cardiovascular diseases&#xD;
      the biological structure of these hormones may be altered, thus reducing their favorable&#xD;
      protective activities. New studies indicate that early and moderate hypertension is&#xD;
      associated with a derangement of the natriuretic peptide system which is characterized by the&#xD;
      lack of activation of biologically active ANP and BNP, while severe hypertension is&#xD;
      characterized by cardiac release of altered molecular forms of ANP and BNP that have reduced&#xD;
      biological properties and/or enhanced degradation.&#xD;
&#xD;
      The broad objective of proposal is to advance the biology and therapeutics of the natriuretic&#xD;
      peptides (NPs) with a special focus on the cardiac peptide BNP in human hypertension. The&#xD;
      investigators' proposal is based upon the biological properties of BNP (i.e., natriuretic,&#xD;
      renin-angiotensin-aldosterone suppressing, vasodilating, anti-fibrotic, anti-hypertrophic and&#xD;
      positive lusitropic), its mechanistic role in human hypertension, and thus its potential as&#xD;
      an innovative chronic protein therapeutic to enhance the treatment of patients with&#xD;
      uncontrolled and or resistant hypertension. Importantly, BNP is an endocrine hormone normally&#xD;
      produced by the human heart, and its use as therapeutic agent has been approved in USA for&#xD;
      more than a decade and has been proven to be safe.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Original PI left the institution, and lack of funding.&#xD;
  </why_stopped>
  <start_date type="Actual">April 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Systolic Blood Pressure (BP)</measure>
    <time_frame>baseline, treatment day 1, treatment day 2</time_frame>
    <description>The change in BP with treatment over 7 days was assessed by the mean BP on admission, (treatment day 1) mean BP 23 hours after the first injection of BNP, and mean BP 23 hours after the second injection of BNP (treatment day 2). Treatment day 2 was 7 days after admission.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Nesiritide (BNP)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will receive subcutaneous (SQ) BNP bid for seven consecutive days. The initial starting dose was 5 micrograms/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive SQ placebo bid for seven consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nesiritide (BNP)</intervention_name>
    <description>NATRECORÂ® (nesiritide) is a sterile, purified preparation of human B-type natriuretic peptide (hBNP), and is manufactured from E. coli using recombinant DNA technology. Each 1.5 mg vial contains a white- to off-white lyophilized powder for intravenous (IV) administration after reconstitution.</description>
    <arm_group_label>Nesiritide (BNP)</arm_group_label>
    <other_name>Natrecor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered subcutaneously instead of active drug (nesiritide) in a blind fashion in the second arm of the study.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Subjects with resistant hypertension as defined by the Seventh Report of the Joint National&#xD;
        Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC&#xD;
        7) guidelines, systolic blood pressure and/or diastolic blood pressure &gt; 140/90 mm Hg. For&#xD;
        patients with hypertension and diabetes or renal disease, blood pressure &gt; 130/80 mm Hg&#xD;
        despite treatment with diuretic, sympathetic depressant and vasodilators.&#xD;
&#xD;
        Medications may include a three drug regimen including:&#xD;
&#xD;
          -  diuretic at therapeutic dose&#xD;
&#xD;
          -  a second line agent such as sympatholytic (e.g. beta-blockade, central agent such as&#xD;
             clonidine) or angiotensin converting enzyme inhibitor (ACEi) / angiotensin receptor&#xD;
             blocker (ARB) or calcium channel blocker (CCB).&#xD;
&#xD;
          -  third line agent including one of the above and/or direct vasodilator, such as&#xD;
             hydralazine or minoxidil.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Congestive Heart Failure (any New York Heart Association (NYHA) class)&#xD;
&#xD;
          -  Ejection Fraction &lt; 50%&#xD;
&#xD;
          -  Known renal artery stenosis&#xD;
&#xD;
          -  Myocardial infarction within 3 months of screening&#xD;
&#xD;
          -  Unstable angina within 14 days of screening, or any evidence of myocardial ischemia&#xD;
&#xD;
          -  Moderate to severe pulmonary hypertension&#xD;
&#xD;
          -  Valvular stenosis, hypertrophic, restrictive or obstructive cardiomyopathy,&#xD;
             constrictive pericarditis, primary pulmonary hypertension, or biopsy proven active&#xD;
             myocarditis&#xD;
&#xD;
          -  Sustained ventricular tachycardia or ventricular fibrillation within 14 days of&#xD;
             screening&#xD;
&#xD;
          -  Sustained Atrial Fibrillation&#xD;
&#xD;
          -  Second or third degree atrioventricular (AV) block without a permanent cardiac&#xD;
             pacemaker&#xD;
&#xD;
          -  Cerebral vascular accident within 3 months of screening, or other evidence of&#xD;
             significantly compromised central nervous system perfusion&#xD;
&#xD;
          -  Total bilirubin of &gt; 1.5 mg/dL or aspartate aminotransferase (AST) and alanine&#xD;
             aminotransferase (ALT) 1.5 times the upper limit of normal range&#xD;
&#xD;
          -  Renal insufficiency assessed by calculated Glomerular Filtration Rate (GFR) &lt; 30&#xD;
             ml/min (Cockcroft-Gault equation)&#xD;
&#xD;
          -  Serum sodium of &lt; 125 milliequivalent (mEq)/dL or &gt; 160 mEq/dL&#xD;
&#xD;
          -  Serum potassium of &lt; 3.0 mEq/dL or &gt; 5.5 mEq/dL&#xD;
&#xD;
          -  Women taking hormonal contraceptives&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Body mass index (BMI) &gt; 35&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John C Burnett, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>January 12, 2012</study_first_submitted>
  <study_first_submitted_qc>January 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2012</study_first_posted>
  <results_first_submitted>April 27, 2017</results_first_submitted>
  <results_first_submitted_qc>October 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 20, 2017</results_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>John C Burnett</investigator_full_name>
    <investigator_title>Professor of Medicine and Physiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited at Mayo Clinic in Rochester, Minnesota.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Nesiritide (BNP)</title>
          <description>Subjects will receive subcutaneous (SQ) BNP bid for seven consecutive days. The initial starting dose was 5 micrograms/kg.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects will receive SQ placebo bid for seven consecutive days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen failure</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nesiritide (BNP)</title>
          <description>Subjects will receive subcutaneous (SQ) BNP bid for seven consecutive days. The initial starting dose was 5 micrograms/kg.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects will receive SQ placebo bid for seven consecutive days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Systolic Blood Pressure (BP)</title>
        <description>The change in BP with treatment over 7 days was assessed by the mean BP on admission, (treatment day 1) mean BP 23 hours after the first injection of BNP, and mean BP 23 hours after the second injection of BNP (treatment day 2). Treatment day 2 was 7 days after admission.</description>
        <time_frame>baseline, treatment day 1, treatment day 2</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nesiritide (BNP)</title>
            <description>Subjects will receive subcutaneous (SQ) Nesiritide (BNP) bid for seven consecutive days. The initial starting dose was 5 micrograms/kg.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects will receive SQ placebo bid for seven consecutive days.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Systolic Blood Pressure (BP)</title>
          <description>The change in BP with treatment over 7 days was assessed by the mean BP on admission, (treatment day 1) mean BP 23 hours after the first injection of BNP, and mean BP 23 hours after the second injection of BNP (treatment day 2). Treatment day 2 was 7 days after admission.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153" spread="9.180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134" spread="9.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129" spread="17.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nesiritide (BNP)</title>
          <description>Subjects will receive subcutaneous (SQ) BNP bid for seven consecutive days. The initial starting dose was 5 micrograms/kg.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects will receive SQ placebo bid for seven consecutive days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was terminated early because the original principal investigator left the institution, and also due to the lack of funding.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. John C. Burnett</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-7932</phone>
      <email>burnett.john@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

